Sharon Ann Erickson

US Patent:

7097840, Aug 29, 2006

Filed:

Mar 16, 2001

Appl. No.:

09/811123

Inventors:

Sharon Erickson - Hillsborough CA, US
Ralph Schwall - Pacifica CA, US
Mark Sliwkowski - San Carlos CA, US
Walter Blattler - Brookline MA, US

Assignee:

Genentech, Inc. - South San Francisco CA
Immunogen, Inc. - Cambridge MA

International Classification:

A61K 39/40

US Classification:

4241781, 4241301, 4241351, 4241411, 4241551, 4241581

Abstract:

The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.

US Patent:

7575748, Aug 18, 2009

Filed:

Jul 17, 2006

Appl. No.:

11/488545

Inventors:

Sharon Erickson - Hillsborough CA, US
Ralph Schwall - Pacifica CA, US
Mark Sliwkowski - San Carlos CA, US
Walter Blattler - Brookline MA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 39/395

US Classification:

4241781, 5303871

Abstract:

The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.

US Patent:

20020035736, Mar 21, 2002

Filed:

Mar 16, 2001

Appl. No.:

09/811115

Inventors:

Sharon Erickson - Hillsborough CA, US
Kathleen King - Pacifica CA, US
Ralph Schwall - Pacifica CA, US

International Classification:

A01K067/027

US Classification:

800/014000, 800/015000, 800/016000, 800/017000, 800/018000, 800/010000

Abstract:

The invention concerns HER2-transgenic non-human mammals, animal models for screening drug candidates for the treatment of diseases and disorders associated with teh overexpression of HER2. In particular, the invention concerns animal models designed to test drug candidates for the treatment of HER2-overexpressing cancers, including breast cancer, that are not responding or poorly responding to current treatments.

US Patent:

20080226659, Sep 18, 2008

Filed:

Dec 3, 2007

Appl. No.:

11/949351

Inventors:

Sharon Erickson - Hillsborough CA, US
Ralph Schwall - Pacifica CA, US
Mark Sliwkowski - San Carlos CA, US
Walter Blattler - Brookline MA, US

International Classification:

A61K 39/395

US Classification:

4241811

Abstract:

The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.

US Patent:

20100136033, Jun 3, 2010

Filed:

Oct 30, 2009

Appl. No.:

12/609737

Inventors:

Sharon Erickson - Hillsborough CA, US
Ralph Schwall - Pacifica CA, US
Mark Sliwkowski - San Carlos CA, US
Walter Blattler - Brookline MA, US

Assignee:

IMMUNOGEN, INC. - Cambridge MA

International Classification:

A61K 39/395
C07K 16/00
A61P 35/00

US Classification:

4241811, 5303919

Abstract:

The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.

US Patent:

20140212411, Jul 31, 2014

Filed:

Sep 19, 2013

Appl. No.:

14/032046

Inventors:

Gail Colbern Schwall - , US
- South San Francisco CA, US
- Waltham MA, US
Sharon ERICKSON - Hillsborough CA, US
Ravi V.J. CHARI - Newton MA, US

Assignee:

GENENTECH, INC. - South San Francisco CA
IMMUNOGEN, INC. - Waltham MA

International Classification:

A61K 47/48
A61K 31/5365
A61K 39/395

US Classification:

4241331, 4241781, 4241811

Abstract:

The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.